Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics

International Journal of Radiation Oncology Biology Physics

Volumn 88, Issue 1, 2014, Pages 195-203

  Zhang, Hao ^a   Tan, Shan ^a,b   Chen, Wengen ^a   Kligerman, Seth ^a   Kim, Grace ^a   D'Souza, Warren D ^a   Suntharalingam, Mohan ^a   Lu, Wei ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIATION THERAPIES; INTENSITY DISTRIBUTION; LOGISTIC REGRESSION MODELS; METHODS AND MATERIALS; NEOADJUVANT CHEMORADIATION; POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHIES; RECEIVER OPERATING CHARACTERISTIC CURVES; STANDARDIZED UPTAKE VALUES;

DISEASES; PATHOLOGY; PATIENT TREATMENT; POPULATION STATISTICS; POSITRON EMISSION TOMOGRAPHY; SUPPORT VECTOR MACHINES;

TUMORS;

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE MODEL; DISTANT METASTASIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LOWER ESOPHAGUS SPHINCTER; MALE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; PATHOLOGIC RESPONSE MODEL; PATHOLOGIST; PET SCANNER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84890559948     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.09.037     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts & Figures 2012. Available from: www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts- figures-2012. Accessed on May 13, 2013.
2. J. Tepper, M.J. Krasna, and D. Niedzwiecki Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 J Clin Oncol 26 2008 1086 1092
3. A.M. Monjazeb, G. Riedlinger, and M. Aklilu Outcomes of patients with esophageal cancer staged with [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET): Can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 28 2011 4714 4721
4. M. Stahl, M. Stuschke, and N. Lehmann Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus J Clin Oncol 23 2005 2310 2317
5. L. Bedenne, P. Michel, and O. Bouche Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 J Clin Oncol 25 2007 1160 1168
6. S.R. Prasad, K.S. Jhaveri, and S. Saini CT tumor measurement for therapeutic response assessment: Comparison of unidimensional, bidimensional, and volumetric techniques initial observations Radiology 225 2002 416 419
7. F. O'Sullivan, S. Roy, and J. O'Sullivan Incorporation of tumor shape into an assessment of spatial heterogeneity for human sarcomas imaged with FDG-PET Biostatistics 6 2005 293 301
8. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors J Nucl Med 50 2009 122S 150S
9. F. Tixier, C.C. Le Rest, and M. Hatt Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer J Nucl Med 52 2011 369 378
10. S. Tan, S. Kligerman, and W. Chen Spatial-temporal 18F-FDG PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiotherapy Int J Radiat Oncol Biol Phys 85 2013 1375 1382
11. M. Vaidya, K.M. Creach, and J. Frye Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer Radiother Oncol 102 2012 239 245
12. R.M. Kwee Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: A systematic review Radiology 254 2010 707 717
13. American Joint Committee on Cancer AJCC Cancer Staging Manual 6th ed. 2002 Springer New York
14. M. Koshy, B.D. Greenwald, and P. Hausner Outcomes after trimodality therapy for esophageal cancer: The impact of histology on failure patterns Am J Clin Oncol 34 2011 259 264
15. A.M. Mandard, F. Dalibard, and J.C. Mandard Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations Cancer 73 1994 2680 2686
16. S.B. Kotsiantis Supervised machine learning: A review of classification techniques Informatica 31 2007 249 269
17. J. Hua, Z. Xiong, and J. Lowey Optimal number of features as a function of sample size for various classification rules Bioinformatics 21 2005 1509 1515
18. P. Jayachandran, R.K. Pai, and A. Quon Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer Int J Radiat Oncol Biol Phys 84 2012 471 477
19. C.H. Chiu, Y.K. Chao, and H.K. Chang Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: Does delayed surgery impact outcome? Ann Surg Oncol 2013 [Epub ahead of print]
20. I. Guyon, J. Weston, and S. Barnhill Gene selection for cancer classification using support vector machines Mach Learn 46 2002 389 422
21. B.J. Krause, K. Herrmann, and H. Wieder 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer J Nucl Med 50 Suppl 1 2009 89S 96S
22. M. Westerterp, H.L. van Westreenen, and J.B. Reitsma Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review Radiology 236 2005 841 851
23. S.G. Swisher, M. Maish, and J.J. Erasmus Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer Ann Thorac Surg 78 2004 1152 1160 discussion 1152-1160
24. E.A. Levine, M.R. Farmer, and P. Clark Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (F-18-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer Ann Surg 243 2006 472 478
25. K. Kubota From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology Ann Nucl Med 15 2001 471 486
26. S.M. Larson, Y. Erdi, and T. Akhurst Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: The visual response score and the change in total lesion glycolysis Clin Positron Imaging 2 1999 159 171
27. S. Zhao, Y. Kuge, and T. Mochizuki Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor J Nucl Med 46 2005 675 682
28. A. Marusyk, and K. Polyak Tumor heterogeneity: Causes and consequences Biochim Biophys Acta 1805 2010 105 117
29. J.Y. Kim, A.M. Correa, and A.A. Vaporciyan Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg 93 2012 207 212 discussion 212-213
30. A. Ruol, C. Rizzetto, and C. Castoro Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: Does delayed surgery have an impact on outcome? Ann Surg 252 2010 788 796